 |
市场调查报告书
商品编码
1672642
血浆衍生药物市场（按产品、应用、分销管道和地区划分）Plasma Derived Medicine Market, By Product, By Application, By Distribution Channel, By Geography |
||||||
2025 年全球血浆药物市场规模估计为 198.7 亿美元，预计到 2032 年将达到 327.7 亿美元，2025 年至 2032 年的年复合成长率（CAGR）为 7.4%。
| 报告范围 | 报告详细信息 | ||
|---|---|---|---|
| 基准年 | 2024 | 2025 年市场规模 | 198.7亿美元 |
| 效能资料 | 从 2020 年到 2024 年 | 预测期 | 2025 至 2032 年 |
| 预测期：2025-2032年复合年增长率： | 7.40％ | 2032 年价值预测 | 327.7亿美元 |
血浆药物是利用人体血浆作为原料製成的。这些药物用于治疗多种罕见疾病，包括免疫不全症、出血性疾病和神经系统疾病。全球范围内罕见疾病发病率的不断上升以及治疗方案的进步可能会推动对血浆疗法的需求。此外，政府和私营部门加大对基于血浆衍生物的创新治疗方法开发的投资可能会推动市场成长。然而，血浆衍生药物的高成本和严格的法律规范可能会阻碍市场的成长。对实证医学的日益重视和对新兴市场的日益关注，很可能在不久的将来为血浆药物提供者创造商机。
市场动态：
全球血浆衍生药物市场的成长是由世界范围内罕见免疫和出血性疾病的日益流行所推动的。越来越多地采用血浆疗法治疗免疫性血小板减少性疾病、低丙种球蛋白血症和神经系统疾病等疾病，正在推动市场成长。医疗保健支出的增加和支持血浆衍生物製造的不断发展的监管指南也将推动市场成长。市场参与企业开发创新的分馏技术和专门的生物加工平台将促进血浆衍生药物的生产。然而，血浆采集的高成本和复杂的製造过程可能会阻碍血浆衍生疗法的快速商业化。有关安全性和功效评估的严格规定可能会给参与企业带来挑战。在亚洲和拉丁美洲的新兴国家，由于替代疗法有限，需求正在成长，这可能在不久的将来为製造商创造新的商机。
本研究的主要特点
本报告对全球血浆衍生药物市场进行了详细分析，并给出了预测期（2025-2032 年）的市场规模（十亿美元）和年复合成长率（CAGR%），假设 2024 年为基准年。
它揭示了各个领域的潜在商机并解释了该市场的有吸引力的投资提案矩阵。
它还提供了对市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的重要见解。
全球血浆衍生药物市场的主要企业简介是根据公司亮点、产品系列、关键亮点、业绩和策略等参数进行的。
主要企业包括工业公司、CSL 有限公司、Grifols SA、Octapharma AG、Kedrion SpA 等。
本报告的见解将使负责人和企业经营团队能够就未来产品发布、新兴趋势、市场扩张和行销策略做出明智的决策。
全球血浆衍生药物市场报告迎合了该行业的各个相关人员，包括投资者、供应商、产品製造商、经销商、新进入者和金融分析师。
相关人员可以透过分析全球血浆衍生药物市场所使用的各种策略矩阵来促进他们的决策。
目录
第一章 调查目的与前提条件
- 研究目标
- 先决条件
- 简称
第二章 市场展望
- 报告描述
- 市场定义和范围
- 执行摘要
第三章市场动态、法规与趋势分析
- 市场动态
- 影响分析
- 主要亮点
- 监管情景
- 产品发布/核准
- PEST分析
- PORTER 分析
- 併购情景
4. 2020 年至 2032 年全球血浆衍生药物市场（按产品划分）（十亿美元）
- 免疫球蛋白
- 凝血因子
- 白蛋白
- 其他的
5. 2020 年至 2032 年全球血浆衍生药物市场（按应用划分）（十亿美元）
- 骨盆腔发炎 (PID)
- 出血性疾病
- Alpha-1 抗胰蛋白酶缺乏症 (AATD)
- 遗传性血管性水肿（HAE）
- 慢性脱髓鞘多发性神经炎
- 格林-巴利综合症
- 多灶性运动神经病变
- 肝臟疾病
- 原发性免疫性血小板减少性疾病
- 感染疾病
- 其他罕见疾病
6. 2020-2032 年全球血浆衍生药物市场按分销管道划分（十亿美元）
- 医院药房
- 零售药局
- 网路药局
7. 2020 年至 2032 年全球血浆衍生药物市场（按地区划分）（十亿美元）
- 北美洲
- 拉丁美洲
- 欧洲
- 亚太地区
- 中东
- 非洲
第八章 竞争格局
- CSL Behring
- Takeda Pharmaceutical Company Limited
- Grifols, SA
- Octapharma AG
- Kedrion Biopharma
- LFB SA
- ADMA Biologics, Inc.
- Bio Products Laboratory Ltd.
- China Biologic Products Holdings, Inc.
- Shanghai RAAS Blood Products Co., Ltd.
- HemaCare Corporation
- Sanquin Blood Supply Foundation
- Biotest AG
- Emergent BioSolutions Inc.
- Medac GmbH
- Scripps Laboratories
- BPL（Bio Products Laboratory）
- Fresenius Kabi AG
- Kamada Pharmaceuticals
第 9 章分析师建议
- 命运之轮
- 分析师观点
- 一致的机会图
第十章参考文献与调查方法
- 参考
- 调查方法
- 关于出版商
Global Plasma Derived Medicine Market is estimated to be valued at USD 19.87 Bn in 2025 and is expected to reach USD 32.77 Bn by 2032, growing at a compound annual growth rate (CAGR) of 7.4% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 19.87 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 7.40% | 2032 Value Projection: | USD 32.77 Bn |
Plasma derived medicines are manufactured using human blood plasma as the raw material. These medicines are used for treating various rare diseases like immune deficiency disorders, bleeding disorders, neurological disorders and more. Growing prevalence of rare diseases across the globe and advancements in therapy options can boost demand for plasma derived therapies. Furthermore, rising investments by government and private sectors in developing innovative treatments based on plasma derivatives can drive the market growth. However, high costs associated with plasma derived medication and stringent regulatory frameworks can hamper the market growth. Increasing emphasis on evidence-based treatment and emerging markets in developing nations can offer opportunities for plasma derived medicine providers in the near future.
Market Dynamics:
Global plasma derived medicine market growth is driven by rising prevalence of rare immunological and bleeding disorders worldwide. Growing adoption of plasma therapies to treat conditions like immune thrombocytopenia, hypogammaglobulinemia and neurological disorders can drive the market growth. Increasing healthcare spending coupled with evolving regulatory guidelines supporting manufacture of plasma derivatives can also drive the market growth. Emergence of innovative fractionation techniques and development of specialized bioprocessing infrastructure by market players facilitates the production of plasma derived drugs. However, high costs involved in plasma collection and complex production processes can hamper the rapid commercialization of plasma derived therapy. Stringent regulations regarding safety and efficacy evaluation can pose challenges for market players. Growing demand in emerging Asian and Latin American countries due to limited availability of alternative treatments can offer novel opportunities for manufacturers in the near future.
Key features of the study:
This report provides in-depth analysis of the global plasma derived medicine market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global plasma derived medicine market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Takeda Pharmaceutical Company Ltd., CSL Ltd., Grifols S.A., Octapharma AG, and Kedrion S.p.A
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global plasma derived medicine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global plasma derived medicine market
Detailed Segmentation-
- Product Insights (Revenue, USD Bn, 2020 - 2032)
- Immunoglobulin
- Coagulation factors
- Albumin
- Others
- Application Insights (Revenue, USD Bn, 2020 - 2032)
- Pelvic Inflammatory Disease (PID)
- Bleeding Disorders
- Alpha-1 Antitrypsin Deficiency (AATD)
- Hereditary Angioedema (HAE)
- Chronic Inflammatory Demyelinating Polyneuropathy
- Guillain-Barre Syndrome
- Multifocal Motor Neuropathy
- Liver Diseases
- Primary Immune Thrombocytopenia
- Infections
- Other Orphan Diseases
- Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- CSL Behring
- Takeda Pharmaceutical Company Limited
- Grifols, S.A.
- Octapharma AG
- Kedrion Biopharma
- LFB S.A.
- ADMA Biologics, Inc.
- Bio Products Laboratory Ltd.
- China Biologic Products Holdings, Inc.
- Shanghai RAAS Blood Products Co., Ltd.
- HemaCare Corporation
- Sanquin Blood Supply Foundation
- Biotest AG
- Emergent BioSolutions Inc.
- Medac GmbH
- Scripps Laboratories
- BPL (Bio Products Laboratory)
- Fresenius Kabi AG
- Kamada Pharmaceuticals
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Plasma Derived Medicine Market, By Product
- Global Plasma Derived Medicine Market, By Application
- Global Plasma Derived Medicine Market, By Distribution Channel
- Global Plasma Derived Medicine Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global Plasma Derived Medicine Market, By Product, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Immunoglobulin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Coagulation factors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Albumin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Plasma Derived Medicine Market, By Application, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021- 2032
- Segment Trends
- Pelvic Inflammatory Disease (PID)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Bleeding Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Alpha-1 Antitrypsin Deficiency (AATD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Hereditary Angioedema (HAE)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Chronic Inflammatory Demyelinating Polyneuropathy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Guillain-Barre Syndrome
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Multifocal Motor Neuropathy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Liver Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Primary Immune Thrombocytopenia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Other Orphan Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Plasma Derived Medicine Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021- 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Plasma Derived Medicine Market, By Region, 2020 - 2032, (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025,2028 & 2032, (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country/Sub-region, 2020 - 2032, (USD Bn)
- South Africa
- North Africa
- Central Africa
8. Competitive Landscape
- CSL Behring
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Grifols, S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Octapharma AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Kedrion Biopharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- LFB S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- ADMA Biologics, Inc.
- Bio Products Laboratory Ltd.
- China Biologic Products Holdings, Inc.
- Shanghai RAAS Blood Products Co., Ltd.
- HemaCare Corporation
- Sanquin Blood Supply Foundation
- Biotest AG
- Emergent BioSolutions Inc.
- Medac GmbH
- Scripps Laboratories
- BPL (Bio Products Laboratory)
- Fresenius Kabi AG
- Kamada Pharmaceuticals
9. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
10. References and Research Methodology
- References
- Research Methodology
- About us
